华大基因(300676.SZ)：沙特子公司拟按持股比例对Genalive增资

Group 1 - Genalive Medical Company is a joint venture in which BGI Almanahil Health for Medical Services holds a 50% stake, and it is a wholly-owned subsidiary of BGI Almanahil in Saudi Arabia [1] - On August 21, 2025, BGI Almanahil and Genalive signed a capital increase agreement to raise 44 million Saudi Riyals (approximately 84 million RMB) to support business development [1] - Following the capital increase, Genalive's registered capital will rise from 90.5 million Saudi Riyals to 134.5 million Saudi Riyals, with BGI Almanahil maintaining its 50% ownership stake [1] Group 2 - Genalive won a public hospital three-year outsourcing testing service procurement project worth approximately 950 million RMB from NUPCO in March 2025 [2] - The capital increase aims to ensure Genalive's operational funding needs for the awarded project, enhance its comprehensive business capabilities, and strengthen strategic collaboration with BGI Almanahil [2] - This move aligns with the company's long-term overseas business development strategy and aims to expand its leading position in Saudi Arabia and the Gulf region [2]